176 related articles for article (PubMed ID: 37797807)
1. New epidemiologic trends in cholangiocarcinoma.
Pascale A; Rosmorduc O; Duclos-Vallée JC
Clin Res Hepatol Gastroenterol; 2023 Nov; 47(9):102223. PubMed ID: 37797807
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
Clements O; Eliahoo J; Kim JU; Taylor-Robinson SD; Khan SA
J Hepatol; 2020 Jan; 72(1):95-103. PubMed ID: 31536748
[TBL] [Abstract][Full Text] [Related]
3. Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification.
Walter D; Ferstl P; Waidmann O; Trojan J; Hartmann S; Schnitzbauer AA; Zeuzem S; Kraywinkel K
Liver Int; 2019 Feb; 39(2):316-323. PubMed ID: 30176117
[TBL] [Abstract][Full Text] [Related]
4. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.
Javle M; Lee S; Azad NS; Borad MJ; Kate Kelley R; Sivaraman S; Teschemaker A; Chopra I; Janjan N; Parasuraman S; Bekaii-Saab TS
Oncologist; 2022 Oct; 27(10):874-883. PubMed ID: 35972334
[TBL] [Abstract][Full Text] [Related]
5. Cholangiocarcinoma miscoding in hepatobiliary centres.
Selvadurai S; Mann K; Mithra S; Bridgewater J; Malik H; Khan SA
Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):635-639. PubMed ID: 33032867
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis.
Wongjarupong N; Assavapongpaiboon B; Susantitaphong P; Cheungpasitporn W; Treeprasertsuk S; Rerknimitr R; Chaiteerakij R
BMC Gastroenterol; 2017 Dec; 17(1):149. PubMed ID: 29216833
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis, diagnosis, and management of cholangiocarcinoma.
Ilyas SI; Gores GJ
Gastroenterology; 2013 Dec; 145(6):1215-29. PubMed ID: 24140396
[TBL] [Abstract][Full Text] [Related]
8. Clinical presentation, risk factors and staging systems of cholangiocarcinoma.
Plentz RR; Malek NP
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):245-52. PubMed ID: 25966425
[TBL] [Abstract][Full Text] [Related]
9. Viral hepatitis B and C infections increase the risks of intrahepatic and extrahepatic cholangiocarcinoma: Evidence from a systematic review and meta-analysis.
Tan JH; Zhou WY; Zhou L; Cao RC; Zhang GW
Turk J Gastroenterol; 2020 Mar; 31(3):246-256. PubMed ID: 32343237
[TBL] [Abstract][Full Text] [Related]
10. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
Zen Y
Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
[TBL] [Abstract][Full Text] [Related]
11. Analysis of metastasis and survival between extrahepatic and intrahepatic cholangiocarcinoma: A large population-based study.
Liao P; Cao L; Chen H; Pang SZ
Medicine (Baltimore); 2021 Apr; 100(16):e25635. PubMed ID: 33879742
[TBL] [Abstract][Full Text] [Related]
12. Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland.
Barner-Rasmussen N; Pukkala E; Hadkhale K; Färkkilä M
United European Gastroenterol J; 2021 Dec; 9(10):1128-1135. PubMed ID: 34533900
[TBL] [Abstract][Full Text] [Related]
13. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy.
Donato F; Gelatti U; Tagger A; Favret M; Ribero ML; Callea F; Martelli C; Savio A; Trevisi P; Nardi G
Cancer Causes Control; 2001 Dec; 12(10):959-64. PubMed ID: 11808716
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for cholangiocarcinoma.
Tyson GL; El-Serag HB
Hepatology; 2011 Jul; 54(1):173-84. PubMed ID: 21488076
[TBL] [Abstract][Full Text] [Related]
15. Biliary intraepithelial neoplasia in patients without chronic biliary disease: analysis of liver explants with alcoholic cirrhosis, hepatitis C infection, and noncirrhotic liver diseases.
Wu TT; Levy M; Correa AM; Rosen CB; Abraham SC
Cancer; 2009 Oct; 115(19):4564-75. PubMed ID: 19670455
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus infection and the risk of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma: evidence from a systematic review and meta-analysis of 16 case-control studies.
Li H; Hu B; Zhou ZQ; Guan J; Zhang ZY; Zhou GW
World J Surg Oncol; 2015 Apr; 13():161. PubMed ID: 25903488
[TBL] [Abstract][Full Text] [Related]
17. Clinical treatment of cholangiocarcinoma: an updated comprehensive review.
Elvevi A; Laffusa A; Scaravaglio M; Rossi RE; Longarini R; Stagno AM; Cristoferi L; Ciaccio A; Cortinovis DL; Invernizzi P; Massironi S
Ann Hepatol; 2022; 27(5):100737. PubMed ID: 35809836
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of cholangiocarcinoma.
Bergquist A; von Seth E
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):221-32. PubMed ID: 25966423
[TBL] [Abstract][Full Text] [Related]
19. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
[TBL] [Abstract][Full Text] [Related]
20. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
